How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target
"Over the past year, we have reached an important inflection point. We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results